NL191182C - Werkwijze voor het bereiden van een 6,7-dichloor-1,5-dihydroimidazo[2,1-b]-chinazoline-2(3H)-on; tussenprodukt daarvoor. - Google Patents

Werkwijze voor het bereiden van een 6,7-dichloor-1,5-dihydroimidazo[2,1-b]-chinazoline-2(3H)-on; tussenprodukt daarvoor.

Info

Publication number
NL191182C
NL191182C NL7902825A NL7902825A NL191182C NL 191182 C NL191182 C NL 191182C NL 7902825 A NL7902825 A NL 7902825A NL 7902825 A NL7902825 A NL 7902825A NL 191182 C NL191182 C NL 191182C
Authority
NL
Netherlands
Prior art keywords
dihydroimidazo
quinazoline
dichloro
preparing
intermediate product
Prior art date
Application number
NL7902825A
Other languages
English (en)
Dutch (nl)
Other versions
NL7902825A (nl
NL191182B (nl
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NL7902825A publication Critical patent/NL7902825A/xx
Publication of NL191182B publication Critical patent/NL191182B/xx
Application granted granted Critical
Publication of NL191182C publication Critical patent/NL191182C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
    • C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/12—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL7902825A 1978-04-10 1979-04-10 Werkwijze voor het bereiden van een 6,7-dichloor-1,5-dihydroimidazo[2,1-b]-chinazoline-2(3H)-on; tussenprodukt daarvoor. NL191182C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/894,464 US4146718A (en) 1978-04-10 1978-04-10 Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides

Publications (3)

Publication Number Publication Date
NL7902825A NL7902825A (nl) 1979-10-12
NL191182B NL191182B (nl) 1994-10-03
NL191182C true NL191182C (nl) 1995-03-01

Family

ID=25403115

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7902825A NL191182C (nl) 1978-04-10 1979-04-10 Werkwijze voor het bereiden van een 6,7-dichloor-1,5-dihydroimidazo[2,1-b]-chinazoline-2(3H)-on; tussenprodukt daarvoor.

Country Status (19)

Country Link
US (1) US4146718A (OSRAM)
JP (2) JPS54135794A (OSRAM)
AU (1) AU527748B2 (OSRAM)
BE (1) BE875475A (OSRAM)
CA (1) CA1109067A (OSRAM)
CH (1) CH639079A5 (OSRAM)
DE (1) DE2914494A1 (OSRAM)
DK (1) DK156062C (OSRAM)
FI (1) FI66616C (OSRAM)
FR (1) FR2422649A1 (OSRAM)
GB (1) GB2018765B (OSRAM)
GR (1) GR72937B (OSRAM)
HU (2) HU179424B (OSRAM)
IE (1) IE48150B1 (OSRAM)
NL (1) NL191182C (OSRAM)
SE (2) SE445217B (OSRAM)
SU (1) SU1120923A3 (OSRAM)
YU (1) YU40554B (OSRAM)
ZA (1) ZA791727B (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
US4818273A (en) * 1983-11-14 1989-04-04 The Dow Chemical Company Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
JPH05271200A (ja) * 1991-05-22 1993-10-19 Egyt Gyogyszervegyeszeti Gyar ６，７−ジクロロ−１，５−ジヒドロ−イミダゾ〔２，１−ｂ〕キナゾリン−２〔３Ｈ〕−オンの製造方法
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
US6194420B1 (en) 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
KR100840083B1 (ko) * 2001-10-15 2008-06-19 이 아이 듀폰 디 네모아 앤드 캄파니 무척추 해충 방제를 위한 이미노벤족사진,이미노벤즈티아진 및 이미노퀴나졸린
DE10301105B4 (de) * 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
DK1589973T4 (da) * 2003-01-23 2013-04-08 Shire Biopharmaceuticals Holdings Ireland Ltd Formulering og fremgangsmåder til behandling af thrombocytæmi
AT412873B (de) * 2004-02-20 2005-08-25 Aop Orphan Pharmaceuticals Ag Verfahren zur herstellung von anagrelid hydrochlorid
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2675265A1 (en) * 2007-02-06 2008-07-14 Cipla Limited Process for the preparation of ethyl-n-(2, 3-dichloro-6-nitrobenzyl) glycine hydrochloride
CN101463035A (zh) * 2007-12-19 2009-06-24 华生制药私人有限公司 生产盐酸阿那格雷一水合物的改进方法
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808951D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808953D0 (en) 2008-05-16 2008-06-25 Shire Llc substituted quinazolines
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201004491D0 (en) 2010-03-18 2010-05-05 Shire Llc Quinazoline analogues
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014111444A1 (en) * 2013-01-18 2014-07-24 Synthon B.V. Crystalline form ii of anagrelide hydrochloride monohydrate
WO2014139572A1 (en) * 2013-03-14 2014-09-18 Synthon Bv Process for making anagrelide
WO2014206484A1 (en) 2013-06-28 2014-12-31 Synthon B.V. Process for making anagrelide
CN106854162A (zh) * 2016-12-13 2017-06-16 浙江海正化工股份有限公司 一种2,3‑二氯‑6‑硝基苯胺及其制备方法
CN107903217B (zh) * 2017-11-16 2021-11-23 湖北省宏源药业科技股份有限公司 一种阿那格雷杂质b的制备方法
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794964A (fr) * 1972-02-04 1973-08-02 Bristol Myers Co Nouveaux agents hypotenseurs et procede pour les preparer
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.

Also Published As

Publication number Publication date
US4146718A (en) 1979-03-27
YU83079A (en) 1983-12-31
IE48150B1 (en) 1984-10-17
FI791125A7 (fi) 1979-10-11
BE875475A (fr) 1979-10-10
GB2018765B (en) 1982-08-04
DK156062B (da) 1989-06-19
FI66616B (fi) 1984-07-31
FR2422649A1 (fr) 1979-11-09
SE454990B (sv) 1988-06-13
GR72937B (OSRAM) 1984-01-13
GB2018765A (en) 1979-10-24
DE2914494A1 (de) 1979-10-18
AU4588979A (en) 1979-10-18
FI66616C (fi) 1984-11-12
DK156062C (da) 1989-11-06
HU179424B (en) 1982-10-28
SU1120923A3 (ru) 1984-10-23
ZA791727B (en) 1980-05-28
JPH0222276A (ja) 1990-01-25
JPH0312066B2 (OSRAM) 1991-02-19
SE8404061L (sv) 1984-08-10
CA1109067A (en) 1981-09-15
SE445217B (sv) 1986-06-09
DE2914494C2 (OSRAM) 1989-07-20
NL7902825A (nl) 1979-10-12
SE7903198L (sv) 1979-10-11
AU527748B2 (en) 1983-03-24
JPS54135794A (en) 1979-10-22
CH639079A5 (de) 1983-10-31
IE790753L (en) 1979-10-10
NL191182B (nl) 1994-10-03
SE8404061D0 (sv) 1984-08-10
FR2422649B1 (OSRAM) 1983-07-29
HU187562B (en) 1986-01-28
DK144779A (da) 1979-10-11
YU40554B (en) 1986-02-28
JPH0233035B2 (OSRAM) 1990-07-25

Similar Documents

Publication Publication Date Title
NL191182C (nl) Werkwijze voor het bereiden van een 6,7-dichloor-1,5-dihydroimidazo[2,1-b]-chinazoline-2(3H)-on; tussenprodukt daarvoor.
NL188901C (nl) Werkwijze voor het bereiden van een 1alfa-hydroxyvitamine d derivaat, alsmede de daarbij verkregen 1alfa-hydroxy-3,5-cyclovitamine d derivaten.
ZA774238B (en) 5-aroyl-1,2-dihydro-3h-pyrrolo(1,2-a)pyrrole-1-carboxylic acid derivatives and process for the production thereof
NL7904674A (nl) Werkwijze voor de bereiding van een chitosan-glucancom- plex.
NL7704116A (nl) Werkwijze voor de vervaardiging van een slijplichaam.
NL185930B (nl) Werkwijze voor het bereiden van een polyurethanelastomeer.
NL181173B (nl) Werkwijze voor het bereiden van een ontschuimingspreparaat.
HU182153B (en) Process for preparing substituted pyrazolo/1,5-a/pyrimidine derivatives
NL189249B (nl) Werkwijze voor het bereiden van een gasmengsel met een hoog methaangehalte.
NL185668C (nl) Werkwijze voor het bereiden van 7-oxo-4-oxa-2,6-diazabicyclo(3,2,0)hept-2-een derivaten.
NL190814C (nl) Werkwijze voor het bereiden van een polyacetaalcopolymeer.
NL7710573A (nl) Werkwijze voor de bereiding van nieuwe 1h-pyra- zolo(3,4-b)pyridinen.
MY8100357A (en) 1,2-dihydro-3h-pyrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
NL178889C (nl) Werkwijze voor de bereiding van een in water onoplosbaar enzym-preparaat.
NL181372C (nl) Werkwijze voor het verstevigen en voor water ondoorlaatbaar maken van de bodem.
NL190447C (nl) Werkwijze voor de bereiding van methaanthiol.
AU5933980A (en) Imidazo(2,1-b)quinazoline derivatives
NL7706046A (nl) Werkwijze voor de bereiding van nieuwe vincamine en apovincaminederivaten.
NL7802091A (nl) Werkwijze voor het bereiden van een proteinerijk diervoeder.
NL7804934A (nl) Werkwijze voor de vervaardiging van een lichtsas.
NL7900619A (nl) Laagvormige bekleding en werkwijze voor het vervaar- digen hiervan, evenals een werkwijze voor het condi- tioneren van een weefsel met deze bekleding.
NL7808571A (nl) 2,3-polymethyleen-4-oxo-4h-pyrido/1,2-a/pyrimidinen en werkwijze voor de bereiding daarvan.
NL7812472A (nl) Werkwijze voor de vervaardiging van, van een kruisbodem voorziene, zakken.
NL7711521A (nl) Werkwijze voor de bereiding van nieuwe 6-(m-ami- nofenyl)-2,3,5,6,-tetrahydroimidazo (2,1-b) thia- zoolderivaten.
NL7700616A (nl) Werkwijze voor het bereiden van tinii-sulfaat.

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
DNT Communications of changes of names of applicants whose applications have been laid open to public inspection

Free format text: BRISTOL-MYERS SQUIBB COMPANY

V4 Discontinued because of reaching the maximum lifetime of a patent

Free format text: 19990410